---
title: 'Clinical Daily Summary: What Happened on November 11, 2026'
headline: Beam’s sickle cell therapy meets its pivotal-trial goal
description: Amgen’s Sjögren’s disease results and J&J’s bipolar mania data add two
  Phase 3 updates.
url: https://thebench.bio/news/clinical/2026-11-11
topic: clinical
date: '2026-11-11'
covers:
- '2026-11-11'
date_published: '2026-11-11T12:03:18Z'
date_modified: '2026-11-12T00:02:24Z'
tags:
- Clinical
- Industry
- Regulatory
- Research
- Software
sources: 13
publisher: TheBench.Bio
---

# Clinical Daily Summary: What Happened on November 11, 2026

**Beam’s sickle cell therapy meets its pivotal-trial goal**

Amgen’s Sjögren’s disease results and J&J’s bipolar mania data add two Phase 3 updates.

## Today in brief

Beam Therapeutics said risto-cel met BEACON’s primary endpoint, which required 12 months without severe pain crises. [1] [2] Amgen said both dazodalibep regimens reduced systemic disease activity versus placebo in a Phase 3 Sjögren’s disease trial. [3]

Johnson & Johnson reported Phase 3 success for Caplyta in manic episodes of bipolar I disorder and plans to seek approval for that use. [4]

## Beam says risto-cel met its sickle cell trial endpoint

Beam said risto-cel met the primary endpoint in BEACON, an open-label study in severe sickle cell disease. [1] The endpoint required at least 12 consecutive months without severe vaso-occlusive crises, assessed independently. [1] [2] At the October 20 data cutoff, 39 adults and 10 adolescents had received treatment, and 31 had completed the follow-up required for the endpoint. [1] [2]

Beam also said the trial met its primary safety and secondary efficacy endpoints, including a measure of time without hospitalization for severe crises. [1] [2] Beam said it could submit an application to the FDA as soon as late 2026 and plans to present detailed pivotal results in 2027. [1] [2]

## Amgen’s two dazodalibep regimens hit the Phase 3 endpoint

In OASIZ-301, a Phase 3 trial of 648 people with Sjögren’s disease, both dazodalibep regimens reduced systemic disease activity more than placebo at Week 48. [3] The mean disease-activity score fell 5.6 points with 1,500 milligrams every four weeks, versus 3.8 points with placebo. [3] With 3,000 milligrams every 12 weeks, the score fell 5.2 points. [3]

The every-four-weeks regimen also improved patient-reported dryness versus placebo, and treated patients had larger increases in stimulated salivary flow. [3] Treatment effects appeared by Week 4 and continued through Week 48. [3] Nasopharyngitis, urinary tract infection, hypertension and infusion reactions were reported more often with dazodalibep, generally at mild or moderate severity. [3] Serious adverse events and treatment discontinuations due to adverse events were balanced between groups, while malignancy rates were low and similar. [3]

Amgen is also running a Phase 3 study in patients with high symptom burden but low systemic disease activity, along with a long-term extension study. [3]

## Also worth knowing

- PepGen reported mean muscle splicing correction of 46.5% at Week 13 in six people with myotonic dystrophy type 1, alongside improvements in myotonia and grip strength. The company expects additional dose-cohort results in the first half of 2027. [5] [6]
- Lipocine dosed the first participant in BLOOM, a placebo-controlled Phase 3 trial of a 48-hour, at-home oral brexanolone treatment for postpartum depression, with results expected in the second half of 2027. [7]
- Natera and Incyte will test Incyte’s investigational bispecific INCA33890 in a Phase 2 colorectal cancer study, using Natera’s Signatera blood test to monitor minimal residual disease and help determine treatment eligibility. [8]
- Nimbus Therapeutics began first-in-human dosing of NDI-225673, a selective SIK2 inhibitor for immune-mediated inflammatory diseases. Preclinical findings have not established whether the drug will have clinical benefit. [9]
- ImvivaBio said 7 of 8 evaluable patients with refractory systemic lupus erythematosus remained in remission 12 months after receiving its dual-target CAR-T therapy CTA313 in Phase 1. [10] [11]
- A study in non-small-cell lung cancer linked a computational measure of tumor TROP2 distribution to longer progression-free survival with datopotamab deruxtecan, but not with docetaxel. [12]
- An unnamed biotech reported that its experimental treatment was associated with an 87% decrease in treated bleeding rates in one Phase 2 dosing group for Glanzmann thrombasthenia. [13]

## The day in numbers

- **12 months**: Time without severe vaso-occlusive crises required for risto-cel’s BEACON primary endpoint. [1] [2]
- **5.6 vs. 3.8 points**: Mean Week 48 reduction in systemic disease activity with dazodalibep 1,500 mg every four weeks versus placebo. [3]
- **7 of 8**: Evaluable CTA313 recipients in remission at Month 12 in ImvivaBio’s pooled Phase 1 analysis. [10] [11]

## Also published

- [Australia’s largest early-phase clinical trial network expands to Sydney](<https://www.pharmaceutical-technology.com/sponsored/australias-largest-early-phase-clinical-trial-network-expands-to-sydney/>), Pharmaceutical Technology
- [UK's Levicept builds case for osteoarthritis therapy at ACR](<https://pharmaphorum.com/news/uks-levicept-builds-case-osteoarthritis-therapy-acr>), pharmaphorum
- [What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial](<https://www.appliedclinicaltrialsonline.com/view/smaller-biotechs-right-first-apac-phase-trial>), Applied Clinical Trials
- [Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine](<https://www.pharmaceutical-technology.com/news/modernas-ceo-eyes-keytruda-eclipsing-future-for-personalised-cancer-vaccine/>), Pharmaceutical Technology
- [Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices](<https://www.appliedclinicaltrialsonline.com/view/continuous-glucose-monitoring-diabetes-clinical-trials-endpoints-regulatory-guidance-operational-best-practices>), Applied Clinical Trials
- [When Patient Input Should Be Collected in the Clinical Research Process](<https://www.pharmexec.com/view/when-patient-input-should-be-collected-clinical-research-process>), Pharmaceutical Executive
- [Antiviral development in the age of AI: From pre-IND to early stage human trials](<https://pharmaphorum.com/digital/antiviral-development-age-ai-pre-ind-early-stage-human-trials>), pharmaphorum
- [Lessons from recent investigator-initiated trials of gene-editing therapies in China](<https://www.nature.com/articles/s41591-026-04768-x>), Nature Medicine
- [PepGen soars on promising early data for muscular dystrophy drug](<https://www.biopharmadive.com/news/pepgen-myotonic-dystrophy-dm1-drug-results-freedom/874249/>), BioPharma Dive
- [Beam’s base editing therapy for sickle cell hits goal in pivotal trial](<https://www.biopharmadive.com/news/beam-sickle-cell-base-editing-risto-cel-results/874242/>), BioPharma Dive
- [STAT+: PepGen says early trial for muscular dystrophy drug looks promising](<https://www.statnews.com/2026/11/10/muscular-dystrophy-dm1-pepgen-pgn-edodm1-early-results/?utm_campaign=rss>), STAT Biotech
- [What Large Pharma Has Figured Out About APAC That Smaller Biotechs Are Still Learning](<https://www.appliedclinicaltrialsonline.com/view/large-pharma-apac-smaller-biotechs-learning>), Applied Clinical Trials
- [Where AI Can Strengthen Clinical Research, and Where Patient Input is More Important](<https://www.pharmexec.com/view/ai-strengthen-clinical-research-patient-input-important>), Pharmaceutical Executive

## Sources

1. [Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial](<https://www.biopharminternational.com/view/beam-risto-cel-primary-endpoint-sickle-cell-trial>), BioPharm International, 2026-11-11
2. [Beam Therapeutics to seek approval of SCD cell therapy after trial success](<https://www.clinicaltrialsarena.com/news/beam-therapeutics-to-seek-approval-of-scd-cell-therapy-after-trial-success/>), Clinical Trials Arena, 2026-11-10
3. [Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial](<https://www.biopharminternational.com/view/amgen-s-dazodalibep-reduces-systemic-disease-activity-in-phase-3-sj-gren-s-trial>), BioPharm International, 2026-11-11
4. [J&J targets Caplyta label expansion on Phase III bipolar mania success  ](<https://www.clinicaltrialsarena.com/news/johnson-johnson-caplyta-bipolar-type-i-phase-iii-success/>), Clinical Trials Arena, 2026-11-11
5. [PepGen’s DM1 readout hints at functional payoff from splicing correction](<https://www.biocentury.com/article/661550/pepgen-s-dm1-readout-hints-at-functional-payoff-from-splicing-correction?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-11
6. [PepGen’s stock skyrockets on record-breaking DM1 trial data](<https://www.clinicaltrialsarena.com/news/pepgens-stock-skyrockets-on-record-breaking-dm1-trial-data/>), Clinical Trials Arena, 2026-11-11
7. [Lipocine doses first patient in Phase III postpartum depression study](<https://www.clinicaltrialsarena.com/news/first-participant-dosed-lipocines-lpcn-1154-study/>), Clinical Trials Arena, 2026-11-11
8. [Natera and Incyte partner on Phase II colorectal cancer trial](<https://www.clinicaltrialsarena.com/news/natera-incyte-phase-ii-colorectal-cancer-trial/>), Clinical Trials Arena, 2026-11-11
9. [Molecules to Medicines: The Pursuit of Repeatable Drug Discovery](<https://lifescivc.com/2026/11/molecules-to-medicines-the-pursuit-of-repeatable-drug-discovery/?utm_source=rss&utm_medium=rss&utm_campaign=molecules-to-medicines-the-pursuit-of-repeatable-drug-discovery>), LifeSciVC, 2026-11-11
10. [ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months](<https://www.biopharminternational.com/view/imvivabio-s-dual-target-allogeneic-car-t-sustains-lupus-remission-through-12-months>), BioPharm International, 2026-11-11
11. [The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus](<https://www.biopharminternational.com/view/the-biopharm-brief-base-editing-hits-its-mark-in-sickle-cell-a-phase-3-win-in-sj-gren-s-and-off-the-shelf-car-t-in-lupus>), BioPharm International, 2026-11-11
12. [Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer](<https://www.nature.com/articles/s41591-026-04716-9>), Nature Medicine, 2026-11-11
13. [Blood Disorder Treatment Biotech Seeks to Stop the Bleeding Before it Starts](<https://biotechcurrents.substack.com/p/blood-disorder-treatment-biotech>), Biotech Currents, 2026-11-11

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biopharminternational.com/view/beam-risto-cel-primary-endpoint-sickle-cell-trial>
[2]: <https://www.clinicaltrialsarena.com/news/beam-therapeutics-to-seek-approval-of-scd-cell-therapy-after-trial-success/>
[3]: <https://www.biopharminternational.com/view/amgen-s-dazodalibep-reduces-systemic-disease-activity-in-phase-3-sj-gren-s-trial>
[4]: <https://www.clinicaltrialsarena.com/news/johnson-johnson-caplyta-bipolar-type-i-phase-iii-success/>
[5]: <https://www.biocentury.com/article/661550/pepgen-s-dm1-readout-hints-at-functional-payoff-from-splicing-correction?utm_source=bc_rss&utm_medium=rss>
[6]: <https://www.clinicaltrialsarena.com/news/pepgens-stock-skyrockets-on-record-breaking-dm1-trial-data/>
[7]: <https://www.clinicaltrialsarena.com/news/first-participant-dosed-lipocines-lpcn-1154-study/>
[8]: <https://www.clinicaltrialsarena.com/news/natera-incyte-phase-ii-colorectal-cancer-trial/>
[9]: <https://lifescivc.com/2026/11/molecules-to-medicines-the-pursuit-of-repeatable-drug-discovery/?utm_source=rss&utm_medium=rss&utm_campaign=molecules-to-medicines-the-pursuit-of-repeatable-drug-discovery>
[10]: <https://www.biopharminternational.com/view/imvivabio-s-dual-target-allogeneic-car-t-sustains-lupus-remission-through-12-months>
[11]: <https://www.biopharminternational.com/view/the-biopharm-brief-base-editing-hits-its-mark-in-sickle-cell-a-phase-3-win-in-sj-gren-s-and-off-the-shelf-car-t-in-lupus>
[12]: <https://www.nature.com/articles/s41591-026-04716-9>
[13]: <https://biotechcurrents.substack.com/p/blood-disorder-treatment-biotech>
